Natera, Inc. NTRA 深 沪
等待开盘 05-11 09:30:00 美东时间
193.40
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 193.40
- 总市值 1862.71万
- 52周最高 256.36
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 131.8106
- 委 比 0.00%
- 总股本 9.63万
- 历史最高 256.36
- 量 比 0
- 振 幅 0.00%
- 历史最低 1.10
- 每 手 1
- 风险率 30.81%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Natera Positioned To Capture Growing $20 Billion MRD Opportunity-Analyst
William Blair starts Natera coverage, citing MRD growth potential, strong moat, and diversified pipeline supporting long-term outlook.
04-15 02:30
Judge Hands Natera 30% Ongoing Royalty In MRD Patent Battle
Natera rises after a Delaware court grants a 30% ongoing royalty in its MRD patent battle with ArcherDx and Invitae.
04-09 20:19
Natera's Signatera Data Suggests Select Breast Cancer Patients Could Skip Surgery
Natera Signatera data shows MRD-guided therapy may reduce surgery in older breast cancer patients; analysts maintain bullish outlook.
04-01 00:48
Earnings Scheduled For February 26, 2026
Companies Reporting Before The Bell • Enovis (NYSE:ENOV) is estimated to report...
02-26 19:11
Natera Completes Enrollment In ACES-EMB Study Evaluating Prospera Heart Test
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the completion of enrollment in ACES-EMB, the first randomized-controlled trial evaluating whether Natera's Prospera
01-28 21:06
Natera Advances Molecular Residual Disease-Based Risk Stratification With New Multi-Model
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced an advancement in molecular residual disease (MRD)-based risk stratification that is expected to
01-13 21:10
Natera Highlights Signatera Study In Nature Communications
The study examined how Signatera can refine risk assessment in patients with early-stage breast cancer whose tumors resist neoadjuvant therapy (NAT). These cancers often leave behind substantial residual disease and
2025-12-16 21:09
Natera Ends Lawsuit, Clearing Path for NeoGenomics' RaDaR ST Launch
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that Natera voluntarily dismissed its appeal (and NeoGenomics thus dismissed its
2025-12-15 20:24
Natera Buys Foresight To Boost Super-Early Cancer Detection Tech
Natera acquires Foresight Diagnostics for $275 million upfront with potential for $175 million in earnouts.
2025-12-05 23:05
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
2025-11-06 19:12
